Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ASML

ASML Holding NV

May 03 • 04:00PM ET

901.63

Dollar change +31.35
Percentage change 3.60	%

Technology • Semiconductor Equipment & Materials • Netherlands • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Index	NDX	P/E	46.09	EPS (ttm)	19.56	Insider Own	0.06%	Shs Outstand	393.42M	Perf Week	-1.89%
Market Cap	354.72B	Forward P/E	28.26	EPS next Y	31.91	Insider Trans	0.00%	Shs Float	393.19M	Perf Month	-5.43%
Income	7.70B	PEG	2.13	EPS next Q	3.96	Inst Own	18.89%	Short Float	0.25%	Perf Quarter	1.23%
Sales	28.30B	P/S	12.54	EPS this Y	-7.14%	Inst Trans	-1.17%	Short Ratio	0.87	Perf Half Y	48.23%
Book/sh	37.53	P/B	24.03	EPS next Y	58.31%	ROA	19.18%	Short Interest	0.99M	Perf Year	42.05%
Cash/sh	14.84	P/C	60.75	EPS next 5Y	21.61%	ROE	60.35%	52W Range	563.99 - 1056.34	Perf YTD	19.12%
Dividend Est.	6.99 (0.77%)	P/FCF	137.04	EPS past 5Y	24.50%	ROI	38.75%	52W High	-14.65%	Beta	1.48
Dividend TTM	6.55 (0.73%)	Quick Ratio	0.88	Sales past 5Y	19.20%	Gross Margin	51.41%	52W Low	59.86%	ATR (14)	31.25
Dividend Ex-Date	Apr 26, 2024	Current Ratio	1.54	EPS Y/Y TTM	8.13%	Oper. Margin	31.52%	RSI (14)	46.90	Volatility	2.57% 2.88%
Employees	42416	Debt/Eq	0.33	Sales Y/Y TTM	11.43%	Profit Margin	27.23%	Recom	1.74	Target Price	1095.18
Option/Short	Yes / Yes	LT Debt/Eq	0.33	EPS Q/Q	-36.53%	Payout	25.88%	Rel Volume	0.91	Prev Close	870.28
Sales Surprise	-4.23%	EPS Surprise	5.06%	Sales Q/Q	-20.68%	Earnings	Apr 17 BMO	Avg Volume	1.14M	Price	901.63
SMA20	-2.32%	SMA50	-5.23%	SMA200	18.71%	Trades		Volume	1,037,851	Change	3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Initiated	Evercore ISI	Outperform
Feb-22-24	Initiated	HSBC Securities	Buy
Feb-20-24	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-23-24	Initiated	Cantor Fitzgerald	Overweight
Jan-22-24	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-08-24	Upgrade	Kepler	Hold → Buy
Oct-17-23	Initiated	Raymond James	Strong Buy	$725
Sep-15-23	Initiated	Wolfe Research	Outperform
Jul-28-23	Downgrade	Bernstein	Outperform → Mkt Perform	$810 → $785
Jul-21-23	Downgrade	Societe Generale	Buy → Hold
Jun-16-23	Downgrade	New Street	Buy → Neutral
Apr-25-23	Downgrade	Stifel	Buy → Hold
Jan-19-23	Initiated	Bernstein	Outperform
Nov-14-22	Upgrade	Susquehanna	Neutral → Positive	$510 → $850
Nov-08-22	Initiated	Morgan Stanley	Overweight
Oct-21-22	Upgrade	New Street	Neutral → Buy
Oct-20-22	Upgrade	Deutsche Bank	Hold → Buy
Aug-31-22	Upgrade	UBS	Neutral → Buy
Jun-29-22	Initiated	Argus	Buy	$590
Jan-13-22	Resumed	Credit Suisse	Outperform

Show Previous Ratings

May-02-24 08:00AM	Is ASML Stock a Buy Now? (Motley Fool)
06:00AM	Chip Stocks on Sale: 3 Semiconductor Plays to Buy the Dip (InvestorPlace)
04:27AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
Apr-30-24 07:17AM	Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn (InvestorPlace)
Apr-29-24 04:00PM	Nvidia's Woes Are Your Windfall: 3 AI Stocks to Grab Now (InvestorPlace)
10:10AM	Loading…
Apr-27-24 10:10AM	1 Wall Street Analyst Thinks ASML Stock Is Going to $1,000. Is It a Buy Around $872? (Motley Fool)
Apr-26-24 07:45AM	Is ASML's Big Sell-off a Warning Sign to Artificial Intelligence (AI) Investors? (Motley Fool)
07:35AM	3 Unstoppable Tech Stocks to Take You From $50,000 to $250,000 (and Beyond) (InvestorPlace)
Apr-25-24 08:57AM	Analysis-New ASML boss Fouquet must navigate US/China chip war (Reuters)
08:00AM	3 Stocks to Grab Now to Ride the Artificial Intelligence Chip Boom to Riches (InvestorPlace)
05:00AM	You Won't Believe What ASML Told Wall Street Investors (Motley Fool)
Apr-24-24 02:02PM	3 Stocks Set to Surge in the Next Market Rally (InvestorPlace)
11:30AM	ASML discloses 2024 AGM results (GlobeNewswire)
10:37AM	ASML approves Christophe Fouquet as CEO at annual meeting (Reuters)
10:08AM	ASML CEO says US restricts servicing some China equipment, won't hurt earnings (Reuters)
10:03AM	Loading…
10:03AM	UPDATE 1-ASML CEO says US restricts servicing some China equipment, won't hurt earnings (Reuters)
06:37AM	What's Going on With ASML Stock? (Motley Fool)
Apr-23-24 05:06PM	Investor playbook: The biggest earnings surprises so far (Yahoo Finance Video)
09:33AM	Is It Time to Buy ASML Stock Yet? (Motley Fool)
09:00AM	ASML Holding N.V. (ASML) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
04:59AM	ASML eyes Dutch expansion after government commits 2.5 billion (DigiTimes)
Apr-22-24 10:26PM	AMSL, AMAT, MU: Which Semiconductor Stock Is the Best Dip Buy? (TipRanks)
07:23PM	Asia Stocks to Track US Rebound on Profit Optimism: Markets Wrap (Bloomberg)
05:30PM	Update: Market Chatter: ASML Mulling Expansion in Netherlands (MT Newswires)
04:40PM	Massive News for ASML Stock Investors (Motley Fool)
01:33PM	Trade Tracker: Steve Weiss sells ASML Holding (CNBC TV)
11:14AM	Did ASML Just Drop Major Red Flags for Semiconductor Investors? (Motley Fool)
09:42AM	ASML Eyes Dutch Expansion After Government Commits 2.5 Billion (Bloomberg)
08:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
Apr-21-24 11:38AM	Will ASML Be a Trillion-Dollar Stock by 2025? (Motley Fool)
09:14AM	Loading…
Apr-20-24 09:14AM	ASML Investors Are Selling Despite Growing AI Demand. Should You Follow Suit or Buy the Dip? (Motley Fool)
07:30AM	ASML Stock: Buy, Hold, or Sell? (Motley Fool)
Apr-18-24 06:31PM	Corrections & Amplifications (The Wall Street Journal)
11:24AM	Is This the Reason AMD, Nvidia, and Intel Stocks Dropped? (Motley Fool)
11:19AM	Seeking edge over rivals, Intel first to assemble ASML's next-gen chip tool (Reuters)
10:27AM	This $362 billion beyond well-positioned Dutch company is quietly winning the global AI chips race (Fortune)
09:49AM	Heard on the Street: The Chip Recovery Is SlowExcept for AI (The Wall Street Journal)
08:56AM	ASML Holding N.V. (NASDAQ:ASML) Q1 2024 Earnings Call Transcript (Insider Monkey)
05:35AM	1 Reason ASML's Revenue Could Soar in 2025 and Beyond (Motley Fool)
03:43AM	Heard on the Street Wednesday Recap: Equities Losing Favor? (The Wall Street Journal)
Apr-17-24 06:08PM	Why Arm Holdings Stock Took a Dive Today (Motley Fool) -7.09%
04:22PM	These Stocks Moved the Most Today: United Airlines, Travelers, DJT, J.B. Hunt, ASML, Autodesk, and More (Barrons.com)
04:19PM	Chip Gear Giant ASML Misses Q1 Sales Goal, Offers Soft Outlook (Investor's Business Daily)
03:36PM	Heard on the Street: ASMLs Weak Orders Show Chip Makers Caution (The Wall Street Journal)
03:24PM	ASMLs Drop Drags Arm, Micron, and Other Chip Stocks Lower (Barrons.com)
02:05PM	Stocks to Watch Wednesday: United Airlines, ASML, Alcoa, Adidas (The Wall Street Journal)
01:44PM	Why ASML Holding Stock Was Falling Today (Motley Fool)
01:43PM	World faces permanently higher interest rates, warns Bank of England official (The Telegraph)
01:40PM	Tesla investors to vote on Musks pay, Bank of America CEO Brian Moynihan speaks with Yahoo Finance (Yahoo Finance Video)
01:07PM	Trade Tracker: Steve Weiss trims ASML Holding (CNBC TV)
12:46PM	United Airlines, Eli Lilly rise; JB Hunt, Travelers fall, Wednesday, 4/17/2024 (Associated Press Finance)
12:23PM	These Stocks Are Moving the Most Today: United Airlines, Travelers, DJT, J.B. Hunt, ASML, Autodesk, and More (Barrons.com)
12:10PM	European Stocks Tick Up as LVMH, Adidas Help Offset Tech Selloff (Bloomberg)
11:30AM	This analyst isn't worried about ASML chip demand. Here's why (Yahoo Finance Video)
11:15AM	ASML executives expect Chinese demand to remain strong (Reuters)
10:18AM	Why ASML Is Falling Despite a Q1 Profit Beat (Investopedia)
10:12AM	ASML Holding, United Airlines, LVMH: Trending tickers (Yahoo Finance Video)
10:03AM	ASML Stock Dives. Its Earnings Report Sends Jitters Through Chip-Equipment Sector. (Barrons.com)
09:00AM	ASML Orders Dive as Chipmakers Pause High-End Gear Purchases (Bloomberg)
08:51AM	What's Going On With ASML Stock Wednesday? (Benzinga)
06:56AM	Feds Powell Delivers Rate-Cut Blow, Why the Market Is Already Over It. And 5 Other Things to Know Before Markets Open. (Barrons.com)
06:34AM	ASML Orders Miss Forecasts as Chip Makers Await Recovery in Demand (The Wall Street Journal)
06:32AM	ASML Stock Dips On Weak Q1 Results, Bookings (RTT News)
05:52AM	ASML Stock Earnings: ASML Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:03AM	ASML: Q1 Earnings Snapshot (Associated Press Finance)
04:47AM	ASML Stock Dives on Orders Miss. Earnings Report Shows Chip Makers Are Cautious. (Barrons.com)
04:28AM	ASML Has More to Do Later in the Year (The Wall Street Journal)
04:16AM	ASML Stock Dives on Orders Miss. Earnings Show Chip Makers Are Cautious. (Barrons.com)
01:23AM	UPDATE 2-Sales to China support ASML's first-quarter earnings despite weak bookings (Reuters)
01:00AM	ASML reports 5.3 billion total net sales and 1.2 billion net income in Q1 2024 (GlobeNewswire)
Apr-16-24 11:57AM	What's in the Offing for ASML Holding's (ASML) Q1 Earnings? (Zacks)
10:41AM	Why Earnings Season Could Be Great for ASML Holding (ASML) (Zacks)
Apr-15-24 08:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
Apr-14-24 06:30AM	3 Artificial Intelligence (AI) Stocks to Buy With $1,000 and Hold for Forever (Motley Fool)
Apr-13-24 04:10PM	2 Millionaire-Maker Artificial Intelligence (AI) Stocks (Motley Fool)
Apr-12-24 07:45AM	2 Backdoor Stocks to Take Advantage of the AI Revolution (Motley Fool)
Apr-11-24 06:00AM	3 Breakout Growth Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Apr-10-24 05:45PM	ASML (ASML) Dips More Than Broader Market: What You Should Know (Zacks)
09:30AM	Wall Street Analysts See ASML (ASML) as a Buy: Should You Invest? (Zacks)
07:15AM	Could Investing $20,000 in ASML Stock Make You a Millionaire? (Motley Fool)
Apr-09-24 11:42AM	Meet Europes Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven. (Barrons.com)
05:10AM	Better Chip Stock: ASML vs. Lam Research (Motley Fool)
Apr-08-24 08:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
Apr-07-24 10:00AM	Should You Buy ASML Holding Stock Before April 17? (Motley Fool)
09:05AM	ASML Holding Stock Has 23% Upside, According to 1 Wall Street Analyst (Motley Fool)
02:03AM	Analysis-Dutch set to comply with U.S. demands on China exports (Reuters)
Apr-06-24 05:20AM	Here Is My Top Artificial Intelligence Stock to Buy Right Now (Motley Fool)
Apr-05-24 10:55AM	From Granolas to Fab Five, Market Looks for Europes Magnificent Seven (The Wall Street Journal)
09:00AM	Investors Heavily Search ASML Holding N.V. (ASML): Here is What You Need to Know (Zacks)
Apr-04-24 05:22PM	Is ASML Stock Going to $1,150? 1 Wall Street Analyst Thinks So. (Motley Fool)
10:45AM	Taiwanese Chip-Making Giant TSMC Says No Earthquake Damage to Most-Critical Tools (The Wall Street Journal)
09:59AM	Exclusive-Targeting Chinese chips, US to push Dutch on ASML service contracts (Reuters)
09:48AM	Explainer-Why maintaining ASML equipment is the new front in US-China chip war (Reuters)
Apr-03-24 01:39PM	ASML, computer chip firms testify to parliament on tax, policy needs (Reuters)
Mar-31-24 08:53AM	2 Leading Tech Stocks to Buy in 2024 and Beyond (Motley Fool)
04:15AM	Will ASML Be Worth More Than Apple by 2030? (Motley Fool)
Mar-29-24 09:00AM	ASML reports transactions under its current share buyback program (GlobeNewswire)
Mar-28-24 04:05PM	ASML cautions investors regarding Tutanota LLC's "mini-tender" offer (GlobeNewswire)
01:45PM	16 Most Profitable Tech Stocks To Invest In (Insider Monkey)
12:57PM	Dutch Invest 2.5 Billion in Eindhoven to Keep ASML at Home (Bloomberg)

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

Open in Screener

DYN

Dyne Therapeutics Inc

May 03 • 04:00PM ET

26.08

Dollar change +0.08
Percentage change 0.31	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB LABU SCHA VTWO IWO IWC

Index	RUT	P/E	-	EPS (ttm)	-3.97	Insider Own	37.13%	Shs Outstand	61.47M	Perf Week	5.46%
Market Cap	2.12B	Forward P/E	-	EPS next Y	-3.28	Insider Trans	-9.90%	Shs Float	50.99M	Perf Month	-1.40%
Income	-257.40M	PEG	-	EPS next Q	-0.76	Inst Own	58.91%	Short Float	17.70%	Perf Quarter	23.95%
Sales	0.00M	P/S	-	EPS this Y	20.28%	Inst Trans	-3.20%	Short Ratio	7.15	Perf Half Y	257.26%
Book/sh	5.49	P/B	4.75	EPS next Y	-4.02%	ROA	-63.48%	Short Interest	9.02M	Perf Year	116.07%
Cash/sh	5.59	P/C	4.66	EPS next 5Y	-	ROE	-71.50%	52W Range	6.40 - 30.27	Perf YTD	96.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-51.49%	52W High	-13.84%	Beta	1.00
Dividend TTM	-	Quick Ratio	21.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	307.50%	ATR (14)	1.62
Dividend Ex-Date	-	Current Ratio	21.83	EPS Y/Y TTM	-18.88%	Oper. Margin	0.00%	RSI (14)	52.63	Volatility	6.59% 5.76%
Employees	141	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	37.80
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-3.25%	Payout	-	Rel Volume	0.60	Prev Close	26.00
Sales Surprise	-100.00%	EPS Surprise	-1.25%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.26M	Price	26.08
SMA20	2.41%	SMA50	-0.55%	SMA200	64.55%	Trades		Volume	761,928	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
12:28PM	Loading…
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
11:01PM	Loading…
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
06:59PM	Loading…
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace)
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)
Dec-09-22 09:55AM	Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now (Zacks) -5.05%
Dec-08-22 08:10AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 09:55AM	Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know (Zacks) +8.43%
Nov-03-22 07:30AM	Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +9.63%
Nov-02-22 07:30AM	Dyne Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
Oct-31-22 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Oct-12-22 06:45AM	Dyne founder heads up new RNA-editing startup (American City Business Journals)
Oct-11-22 04:10PM	Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress (GlobeNewswire)
Sep-27-22 07:30AM	Dyne Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -9.57%
Sep-12-22 07:00AM	Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During Spotlight on the Clinic Virtual Event (GlobeNewswire)
Sep-06-22 04:30PM	Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +5.32%
07:01AM	Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
07:00AM	Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-29-22 07:30AM	Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development (GlobeNewswire)
Aug-10-22 07:30AM	Dyne Therapeutics Announces Breakthrough Article Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research (GlobeNewswire) +7.75%
Aug-04-22 07:30AM	Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-18-22 10:00AM	Best Momentum Stocks to Buy for July 18th (Zacks) -5.56%
Jul-12-22 02:54PM	Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew (Benzinga) +5.94%
07:30AM	Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-05-22 07:30AM	Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +17.22%
Jul-01-22 06:58AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Jun-03-22 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +5.05%
May-16-22 07:30AM	Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown (GlobeNewswire)
May-02-22 04:05PM	Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +6.77%
Mar-17-22 08:45AM	selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform (ACCESSWIRE)
Mar-10-22 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire)
Mar-03-22 07:30AM	Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors (GlobeNewswire)
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com) -8.68%
Jan-22-22 08:06AM	We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely (Simply Wall St.)
Jan-18-22 04:18PM	Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday (Motley Fool) -12.59%
08:00AM	Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-05-22 07:30AM	Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.93%
Dec-03-21 03:30PM	Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate (Zacks) +5.94%
Dec-02-21 08:30AM	Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy (GlobeNewswire)
Nov-04-21 07:30AM	Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-21 10:41AM	Where Do Hedge Funds Stand On Dyne Therapeutics, Inc. (DYN)? (Insider Monkey)
Oct-13-21 07:45AM	Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day (GlobeNewswire)
Oct-01-21 10:21AM	Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program (Benzinga)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farwell Wildon	Chief Medical Officer	Mar 12 '24	Sale	25.58	1,030	26,347	150,560	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Option Exercise	5.54	50,000	277,000	604,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Option Exercise	5.54	17,825	98,750	159,009	Mar 13 06:04 AM
Brumm Joshua T	CEO & President	Mar 11 '24	Sale	25.67	66,387	1,704,142	537,998	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Sale	25.50	19,601	499,842	139,408	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '24	Sale	25.28	2,672	67,542	119,283	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11 '24	Sale	25.70	2,292	58,904	156,800	Mar 13 06:04 AM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '24	Sale	25.70	2,081	53,482	152,352	Mar 12 09:42 PM
Farwell Wildon	Chief Medical Officer	Mar 11 '24	Sale	25.70	1,585	40,734	151,590	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Option Exercise	5.54	363,343	2,012,920	917,728	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Option Exercise	5.54	90,000	498,600	231,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Option Exercise	5.54	86,252	477,836	208,207	Mar 12 09:57 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Sale	25.93	363,343	9,421,634	554,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Sale	26.24	90,000	2,361,531	141,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Sale	26.22	86,252	2,261,465	121,955	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 08 '24	Sale	26.67	27,199	725,344	159,092	Mar 13 06:04 AM
Farwell Wildon	Chief Medical Officer	Mar 07 '24	Sale	25.86	9,921	256,585	153,175	Mar 11 09:52 PM
Brumm Joshua T	CEO & President	Mar 07 '24	Sale	25.85	9,086	234,873	554,385	Mar 11 09:57 PM
McNeill Jonathan	Chief Business Officer	Mar 07 '24	Sale	25.85	2,434	62,919	141,184	Mar 11 09:50 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 07 '24	Sale	25.85	2,373	61,342	154,433	Mar 11 09:56 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 07 '24	Sale	25.85	2,273	58,757	121,955	Mar 11 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 07 '24	Sale	25.85	1,591	41,127	186,291	Mar 11 09:56 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Option Exercise	5.54	94,480	523,419	657,951	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Option Exercise	0.73	24,260	17,710	167,878	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Option Exercise	1.03	9,311	9,590	133,539	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Sale	29.04	94,480	2,743,718	563,471	Mar 01 09:38 PM
Rhodes Jason P	Director	Mar 01 '24	Sale	30.05	46,534	1,398,347	847,388	Mar 05 05:08 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	29,435	884,522	1,458,691	Mar 05 05:07 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Sale	28.63	24,260	694,495	143,618	Mar 01 09:37 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	17,099	513,825	847,388	Mar 05 05:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Sale	28.25	9,311	262,999	124,228	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Option Exercise	5.54	5,520	30,581	568,991	Mar 01 09:38 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Option Exercise	1.03	3,429	3,532	127,657	Mar 01 09:37 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Option Exercise	0.73	4,268	3,116	147,886	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Sale	27.50	5,520	151,800	563,471	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Sale	27.50	4,268	117,370	143,618	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Sale	27.50	3,429	94,298	124,228	Mar 01 09:37 PM
Rhodes Jason P	Director	Feb 28 '24	Sale	24.84	190,920	4,741,804	864,487	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	154,674	3,841,576	5,698,091	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	36,246	900,228	864,487	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 27 '24	Sale	24.41	368,699	8,998,426	877,806	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	298,702	7,290,088	5,852,765	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	69,997	1,708,338	877,806	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 26 '24	Sale	23.72	248,219	5,886,673	903,527	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	201,095	4,769,096	6,151,467	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	47,124	1,117,577	903,527	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 23 '24	Sale	22.70	196,928	4,470,266	920,843	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	159,542	3,621,603	6,352,562	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	37,386	848,662	920,843	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:59 PM
Rhodes Jason P	Director	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:35 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:35 PM
Rhodes Jason P	Director	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:36 PM
Rhodes Jason P	Director	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:35 PM
Farwell Wildon	Chief Medical Officer	Feb 12 '24	Sale	25.07	5,493	137,710	163,503	Feb 14 04:27 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Option Exercise	0.73	20,000	14,600	163,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 26 07:47 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Sale	24.53	20,000	490,510	143,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Sale	24.34	13,000	316,420	124,228	Jan 26 07:47 PM
Farwell Wildon	Chief Medical Officer	Jan 26 '24	Sale	25.00	100	2,500	168,996	Jan 26 07:49 PM
Kersten Dirk	Director	Jan 09 '24	Buy	17.50	1,714,285	29,999,988	6,416,793	Jan 11 04:31 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Option Exercise	5.16	218,536	1,127,092	803,507	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Option Exercise	1.03	22,674	23,354	199,259	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Option Exercise	0.73	2,009	1,467	145,627	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Sale	18.51	218,536	4,045,958	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Sale	18.13	42,453	769,673	156,806	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Sale	18.04	2,009	36,242	143,618	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Option Exercise	1.03	51,183	52,718	636,154	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Option Exercise	1.03	45,326	46,686	221,911	Jan 04 09:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Option Exercise	0.73	17,991	13,133	161,609	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Sale	19.28	51,183	986,957	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Sale	18.98	45,326	860,313	176,585	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Sale	18.74	17,991	337,062	143,618	Jan 04 09:47 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Sale	18.81	13,000	244,530	124,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 02 '24	Sale	13.10	11,900	155,890	143,618	Jan 04 09:47 PM
Scalzo Richard William	See Remarks	Dec 14 '23	Sale	12.02	2,376	28,560	124,228	Dec 14 04:59 PM
Farwell Wildon	Chief Medical Officer	Dec 12 '23	Sale	10.55	978	10,318	169,096	Dec 12 05:33 PM
Brumm Joshua T	See Remarks	Dec 11 '23	Sale	10.72	7,585	81,311	584,971	Dec 12 05:33 PM
Farwell Wildon	Chief Medical Officer	Dec 11 '23	Sale	10.72	1,688	18,095	170,074	Dec 12 05:33 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Dec 11 '23	Sale	10.72	1,616	17,324	187,882	Dec 12 05:34 PM
Beskrovnaya Oxana	Chief Scientific Officer	Dec 11 '23	Sale	10.72	1,467	15,726	176,585	Dec 12 05:32 PM
Scalzo Richard William	See Remarks	Dec 11 '23	Sale	10.72	1,380	14,794	126,604	Dec 12 05:35 PM
McNeill Jonathan	Chief Business Officer	Dec 11 '23	Sale	10.72	1,245	13,346	155,518	Dec 12 05:34 PM
Scalzo Richard William	See Remarks	Dec 06 '23	Sale	12.01	1,872	22,483	127,984	Dec 06 06:13 PM
Scalzo Richard William	See Remarks	Dec 04 '23	Sale	12.01	681	8,179	129,856	Dec 06 06:13 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Nov 02 '23	Sale	7.40	9,939	73,549	94,605	Nov 02 05:16 PM
Brumm Joshua T	See Remarks	Sep 18 '23	Sale	9.41	12,032	113,221	233,679	Sep 20 04:47 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 18 '23	Sale	9.41	2,672	25,144	104,544	Sep 20 04:48 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 18 '23	Sale	9.41	1,436	13,513	84,334	Sep 20 04:47 PM
Scalzo Richard William	See Remarks	Sep 18 '23	Sale	9.41	1,290	12,139	40,795	Sep 20 04:49 PM
McNeill Jonathan	Chief Business Officer	Sep 18 '23	Sale	9.41	1,261	11,866	60,605	Sep 20 04:49 PM
Brumm Joshua T	See Remarks	Sep 12 '23	Sale	10.41	7,672	79,866	245,711	Sep 13 07:50 PM
Farwell Wildon	Chief Medical Officer	Sep 12 '23	Sale	10.41	1,707	17,770	89,250	Sep 13 07:56 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 12 '23	Sale	10.41	1,635	17,020	107,216	Sep 13 07:51 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ASML

ASML Holding NV

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience